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Beta-adrenergic agents have been used in pregnant womenfor the treatment of premature labor and for the treatment
of asthma. Concerns have been expressed that exposure to ter-
butaline, which is a beta-2 adrenergic agonist, may increase the
risk of autism spectrumdisorders (ASDs) in the offspring. This
hypothesis deserves critical review, given the number of pa-
tients who have been exposed to the drug in the last 2 decades.
The results are important to both the obstetricians and patients
who weigh the risks and benefits of interventions and to the
pediatricians who counsel the families of affected children.
We conducted an examination of the human and animal
studies that have been used to support this hypothesis in a
recent review,1 andwe have reached a different conclusion.We
find no support for the hypothesis that the use of terbutaline as
a tocolytic agent is associated with the subsequent develop-
ment of ASDs.
The ASDs are common neurodevelopmental disorders that
occur in approximately 1 of 150 to 1 of 100 children.2 They are
diagnosed by deficits in social interaction and communication
and by restricted and repetitive behaviors and interests; the
symptoms appear during the first 3 years of life.3
Family and twin studies demonstrate that these disorders are
heritable, with estimates of heritability approaching 90%.4 How-
ever, the genetic etiology is complex, withmany loci involved and
none that accounts formore than a small fraction of cases.5Many
developmental pathways seem to be involved and include those
that have roles in initiating or maintaining synapses.6,7 The pen-
etrance of the genetic liability factors is variable so that symptoms
differ, even in pairs of monozygotic twins.8 The largest genome
scan to date has added to this confusing picture the etiologic role
of structural chromosomal anomalies (copy number variants),
some of which arise de novo.9 This unexpected result has been
verified by other groups.10
The known environmental risk factors for ASDs account for
a small number of cases but are interesting because they share
critical periods of exposure in the first trimester.11 The identi-
fication of environmental risk factors is especially important
because, unlike genetic risk factors, they should be preventable.
Thus, it is reasonable to ask whether there is evidence that
medications, such as terbutaline, to which pregnant women
may be exposed increase the risk for an ASD outcome in the
offspring. Our argument is not with the intent but with the
quality of the evidence presented in the review byWitter et al,1
which we now describe.
Human studies
Is fetal exposure to terbutaline associated with neurobehav-
ioral defects? The review cites Stein et al12 as the source that
shows terbutaline exposure has been associatedwith expressive
language delay; however, that article does not report a study
but the presentation of a “Challenging Case” with responses by
4 pediatricians from different backgrounds. None of the com-
mentators suggested that the patient’s language delaymight be
associated with her prenatal exposure to terbutaline. This
source does not offer any evidence to support the hypothesis of
a link between ASD and exposure to terbutaline.
The second reference that is cited in the article is to a study
that had been reported by several of the same authors of the
review.13 The review states that the earlier paper demonstrated
increased concordance for ASDs in dizygotic twins after ter-
butaline treatment in utero. However, a careful review of the
data found no significant association of concordance with ter-
butaline exposure in the whole twin sample (36 cases). Only
when the investigators divided the sample into smaller sub-
groups and focused on twin pairs who were bothmale and had
no other cases of ASDs in their family were they able to find a
significant association between drug exposure and outcome.
This group of 16 twin pairs should have been at increased risk
for ASDs because they weremale and at decreased risk because
of the absence of ASDs in their families. It is unclear why such
a subgroup would ever be selected for study a priori. If it was
selected a posteriori, then the results should be considered “hy-
pothesis-generating” at best.
Another aspect of this publication deserves comment. For all
comparisons of “exposed” to “nonexposed” twins, 2 twin pairs
with short exposures were counted as “unexposed.” No expla-
nation was given to justify recategorizing these twins. Because
both of these pairs were discordant, moving them to the unex-
posed category had a major effect on the results. For example,
the probability value for the whole sample difference in con-
cordance between exposed and unexposed pairs was reported
as .157 in the article. Had the briefly exposed pairs been in-
cluded as “exposed,” the probability value would have been
.471. In the selected group of cases that were composed ofmale
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pairswithnoother siblingswhowere diagnosedwithASDs and
in which the authors reported a significant increase in concor-
dance after terbutaline (P! .035), the probability value would
have been .118. Thus, the only significant effect that was re-
ported for concordance is dependent on the reclassification of
briefly exposed twin pairs. The authors might argue that the
relative risks for their comparisons are "1, but they are not
significantly "1. That is the reason confidence intervals are
calculated.
As evidence that terbutaline exposure for tocolysis or asthma
is associated with autism, the publication cites an oral presen-
tation at a meeting.14 We were not able to access the presenta-
tion at the URL, but the full report of that study is now avail-
able.15 The design of the study was peculiar, in that the 8
terbutaline-exposed recruited children (from just 2 families)
had been diagnosed with autism already. Their performance
on a battery of neuropsychologic tests was reported to differ
from the performance of typically developing children. It is not
clear how this result can be interpreted to support a teratogenic
effect of terbutaline, because subjects with an ASD diagnosis
surely would be expected to differ in many ways from subjects
without a diagnosis. The design makes the study uninterpre-
table.
Another line of evidence that was offered to support the hy-
pothesis that beta-2-adrenergic agonists are harmful to the
conceptus is a study that examined the risk of anASDdiagnosis
in the offspring ofmothers who have autoimmune disorders.16
The review described this as a study of asthma and suggested
that the risk must be related to the use of beta-2-adrenergic
agonists by patients with asthma. However, the only autoim-
mune condition that was a significant risk factor in the cited
studywas psoriasis, which is a condition that is not treatedwith
these agonists.
The fifth reference is a personal communication about an
unpublished study. An abstract of that study is available.17 The
authors of the article under review contended that the data
showed that beta-2-adrenergic agonist exposure during early
pregnancy produces an increased risk for ASDs. In contrast,
the abstract reported no such finding; instead, there was no
effect of exposure in the first, second, or third trimester. The
only significant effect was from the use of beta-2-adrenergic
agonists before conception. These results do not support the
hypothesis that terbutaline exposure in the third trimester in-
creases the risk of ASD.
Although the issues that we have identified herein address a
fraction of the review article, they suggest a very loose interpre-
tation of the findings in the literature. Although we respect the
right of authors to select studies that support their views, the
scientific community would expect an accurate description
and a balanced report of the studies that are cited.
Animal studies
The review describes many animal studies to support the hy-
pothesis that terbutaline is teratogenic in late pregnancy,which
leads to lasting changes in neurotransmitter function, behav-
ior, and brain morphologic condition.1 However, it is impor-
tant to note that the studies that are cited come almost exclu-
sively from 1 research group and use the same dose at the same
stage of development for the same number of repeated doses. If
there is any error in the dose or timing or duration of exposure
that was chosen tomimic terbutaline as a tocolytic therapy, it is
shared by all the articles that were cited.
The dose that was selected was based on pharmacologic ev-
idence that adult rats clear terbutaline more rapidly than adult
humans.18,19 Therefore, the dose to which rats were exposed
was purposely higher than the doses that typically are admin-
istered to women in preterm labor. However, it is well known
that developing humans and rats donot clear xenobiotics at the
same rate as adults.20 The problem is that no data are available
that compare clearance rates in the human fetus and the neo-
natal rat (a stage of rat development often used to model the
third trimester of human pregnancy). Without that informa-
tion, there is no way to judge whether the doses in the rat
studies are equivalent to those used in humans. Similarly, the
only data available are from animals that were given repeated
doses over 4 days. What would be the corresponding length of
exposure in humans? We do not know.
None of the studies provide information on the dose-re-
sponse curve of terbutaline exposure in neonatal rats for the
endpoints that were measured. This information is needed to
interpret the risk of teratogenicity after terbutaline exposure.
Very few teratogens have been studied extensively for their
dose-response characteristics; however, when many laborato-
ries perform studies of the same teratogen, there are often
enough differences in method between studies to offer some
insights into the importance of dose, timing, and duration of
exposure. This information does not exist with terbutaline.
In the review, the neuropathologic evidence of terbutaline-
exposed rats is described as similar to the neuropathologic ev-
idence that is reported for human cases with an ASD diagno-
sis.21 The accuracy of this claim is not easy to assess because of
the brain regions that were studied in the animal model (hip-
pocampus, somatosensory cortex, and cerebellum), only the
cerebellum has been observed consistently to be abnormal in
human cases.22,23 The animal finding of reduced Purkinje cell
numbers does agree with the human findings. The result of
reduced size of cortical neurons in the exposed animals is not
similar to anything that has been reported in humans. Finally,
there is the result of gliosis that was observed in the CA3 region
of the hippocampus in the treated rats. Most pathology studies
in cases of ASD have not reported the presence of gliosis. How-
ever, Bailey et al23 did report astrogliosis that was restricted to
the cerebellum in 3 of their 6 cases. Vargas et al24 observed and
quantified widespread astrogliosis and microgliosis in each of
their human cases. The glial reactivity was greatest in the cer-
ebellum. The animal finding of gliosis that was limited to 1
region of the hippocampus does not appear similar to any of
the human findings. However, subsequent to the publication
of the article by Vargas et al in 2005, the same group of inves-
tigators who reported the very restricted gliosis in 2004 used
the immunocytochemicalmethods ofVargas et al and reported
widespread astrogliosis and microgliosis in both grey matter
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and white matter of cortex and cerebellum in terbutaline-ex-
posed rats.25 The meaning of these results is not clear because
gliosis is not a finding that is restricted to autism.
The authors of the review describe the behavioral effects that
were reported in rats that were exposed in the neonatal period
to terbutaline as “similar to those found in autism.”25 The sig-
nificant effects that were observed included increased activity
in an open field and increased reactivity to noise. These effects
are so nonspecific that they can hardly be described as confirm-
ing parallelism with autism. The same study included 1 mea-
sure that is a much better test of parallelism.25 Prepulse inhi-
bition was measured in terbutaline-exposed rats and control
animals. This neurophysiologicmeasure clearly is depressed in
human cases of ASD26,27 and in a popular animal model of
autism that was based on exposure of rat embryos to valproic
acid at the time of neural tube closure.28 In contrast, terbuta-
line exposure had no effect on prepulse inhibition. Thus, the
idea that terbutaline-exposed animals exhibit behaviors simi-
lar to those observed in autism is not convincing.
Comment
An important issue not addressed byWitter et al1 is the fact that
premature birth itself is associated with an increase in the risk
of neurobehavioral problems that include ASDs. For example,
a recent article by MacKay et al29 examined the length of ges-
tation and the later need for special educational services. De-
livery at #40 weeks of gestation was associated with a signifi-
cantly increased risk of educational problems over the whole
range of gestation. A recent paper by Buckmayer et al30 ana-
lyzed the effect of prematurity on ASDs in an unusually large
number of cases. The result was that the significant odds ratio
for the whole sample disappeared if analyses controlled for
indications of morbidity during gestation (eg, cases with con-
genital malformations) or at the time of birth (eg, cases with
low Apgar scores). Thus, it remains unclear whether prematu-
rity is an etiologic factor in the development of ASDs or
whether it is simply an indication that the conceptus has sus-
tained harm in some way.
Indeed, one of the studies that Witter et al1 describe is an
excellent demonstration of the idea that even threatened pre-
mature delivery may be evidence of injury. Pitzer et al31 com-
pared 4 groups for neurologic and psychiatric morbidity in
childhood. Two groups were born prematurely, one group
without treatment and one group with unsuccessful tocolysis.
Compared with children who were born at term without inci-
dent, both groups who were born early had elevated rates of
neurobehavioral problems, and they did not differ from each
other. The fourth group included children who were born at
term after successful tocolytic treatment. The rate of neurobe-
havioral problems in this group was much higher than that
seen in children whowere born at termwithout treatment, but
it was similar to the 2 groups who were born prematurely.
Witter et al1 interpret the study as supporting the idea that
longer duration of therapy is critical to an adverse outcome,
which assumes that the children who came to term were ex-
posed for longer than those whowere born prematurely. How-
ever, Pitzer’s group31 examined a subset of cases for whom the
duration of exposure and cumulative dose were known. The
authors reported that the group that was born prematurely was
treated for amedian of 18 days, with amedian cumulative dose
of 66 mg; the group that was born at term was treated for a
median of 10 days, with a median cumulative dose of 29 mg.
The simplest conclusion to be drawn from this study is that
tocolysis has no effect on neurobehavioral outcomes, but
threatened premature labormay have a substantial effect, even
if it is treated successfully.
Several publications have addressed the use of beta-2 adren-
ergic agonists, including terbutaline, for the treatment of pre-
term labor. Terbutaline readily crosses the human placenta.32
In review articles by Lam et al33 and Goldenberg,34 the benefits
of beta-2-adrenergic agonists in general, and terbutaline in
particular, are discussed. Surely, larger human studies with
long-term follow upmight raise new concerns, but the present
literature does not support the hypothesis that beta-2 adrener-
gic agonists that are used for tocolysis are associated with ASDs
in the offspring. There is no reason tomake recommendations
for clinical care based on an unsubstantiated hypothesis. f
REFERENCES
1. Witter FR, Zimmerman AW, Reichmann, JP, Connors SL. In utero beta
2 adrenergic agonist exposure and adverse neurophysiologic and behav-
ioral outcomes. Am J Obstet Gynecol 2009;201:553-9.
2. Chakrabarti S, Fombonne E. Pervasive developmental disorders in
preschool children: confirmation of high prevalence. Am J Psychiatry
2005;162:1133-41.
3. American Psychiatric Association. Diagnostic and statistical manual of
mental disorders (IV). Washington, DC: American Psychiatric Association;
1994.
4. Bailey A, Le Couteu A, Gottesman I, et al. Autism as a strongly genetic
disorder: evidence from a British twin study. Psych Med 1995;25:63-77.
5. Geshwind DH. Advances in autism. Annu Rev Med 2009;60:367-80.
6. Jamain S, Quach H, Betancur C, et al. Mutations of the X-linked genes
encoding neuroligins NLGN3 andNLGN4 are associatedwith autism. Nat
Genet 2003;34:27-9.
7. Durand CM, Betancur C, Boeckers, et al. Mutations in the gene en-
coding the synaptic scaffolding protein SHANK3 are associated with
autism spectrum disorders. Nat Genet 2007;39:25-7.
8. Le Couteur A, Bailey A, Goode S, et al. A broader phenotype of autism:
the clinical spectrum in twins. J Psychol Psychiatry 1996;37:785-801.
9. Autism Genome Project Consortium (AGPC), Szatmari P, Paterson
AD, et al. Mapping autism risk loci using genetic linkage and chromo-
somal rearrangements. Nat Genet 2007;39:319-28.
10. Sebat J, Lakshmi B, Malhotra D, et al. Strong association of de novo
copy number mutations with autism. Science 2007;316:445-9.
11. Arndt TL, Stodgell CJ, Rodier PM. The teratology of autism. Int J
Devel Neurosci 2005;23:189-99.
12. Stein MT, Parker S, Coplan J, Feldman H. Expressive language delay
in a toddler. Pediatrics 2001;107:905-9.
13. Connors SL, Crowell DE, Eberhart CG, et al. Beta 2-adrenergic re-
ceptor activation and genetic polymorphisms in autism: data from dizy-
gotic twins. J Child Neurol 2005;20:876-84.
14. Thrasher JD, Kilburn KY, Immers IB. Autism, terbutaline and neuro-
logical impairment: Ramazzi days 2007: 25th Anniversary Jubilee, Capri
Italy.
15. Kilburn KH, Thrasher JD, Immers NB. Do terbutaline and mold-asso-
ciated impairments of the brain and lung relate to autism? Toxicol Ind
Health 2009;25:703-10.
www.AJOG.org Editorial Commentary
FEBRUARY 2011 American Journal of Obstetrics& Gynecology 93
16. Croen LA, Grether JK, Yoshida CK, Odouli R, Van de Water J. Ma-
ternal autoimmune diseases, asthma and allergies, and childhood autism
spectrum disorders: a case-control study. Arch Pediatr Adolesc Med
2005;159:151-7.
17. Croen L, Connors SL, Matevia M, Newschaffer C, Zimmerman AW.
Prenatal exposure to beta-2- adrenergic agonists and risk of autism spec-
trum disorders. 2009. Available at: http://imfar.confex.com/2009/
webprogram/Paper3971.html. Accessed Oct. 10, 2009.
18. Aldridge JR,Meyer A, Seidler FJ, Slotkin TA. Developmental exposure
to terbutaline and chlorpyrifos: pharmacotherapy of preterm labor and an
environmental neurotoxicant converge on sertonergic systems in neona-
tal rat brain regions. Tox Appl Pharm 2005;203:132-44.
19. Tegner K, Nilsson HT, Persson CGA, Persson K, Ryrfeldt A. Elimina-
tion pathways of terbutaline. Eur J Respir Dis 1984;134:93-100.
20. Ginsberg G, Hattis D, Miller RK, Sonawane B. Pediatric pharmacoki-
netic data: implications for environmental risk assessment for children.
Pediatrics 2004;113:973-83.
21. Rhodes MC, Seidler FJ, Abdel-Rahman A, et al. Terbutaline is a
neurotoxicant: effects on neuroproteins and morphology in cerebellum,
hippocampus, and somatosensory cortex. J Pharmacol Exp Ther 2004;
308:529-37.
22. Kemper TL, Bauman M. Neuropathology of infantile autism. J Neu-
ropathol Exp Neurol 1998;57:645-52.
23. Bailey A, Luthert P, Dean A, et al. A clinicopathological study of
autism. Brain 1998;121:889-905.
24. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA.
Neuroglial activation and neuroinflammation in the brain of patients with
autism. Ann Neurol 2005;57:67-81.
25. Zerrate MC, Pletnikov M, Connors SL, et al. Neuroinflammation and
behavioral abnormalities after neonatal terbutaline treatment in rats: im-
plications for autism. J Pharmacol Exp Ther 2007;322:16-22.
26. McAlonan GM, Daly E, Kumari V, et al. Brain anatomy and sensori-
motor gating in Asperger’s syndrome. Brain 2002;127:1594-606.
27. Perry W, Minassian A, Lopez B, Maron L, Lincoln A. Sensorimotor
gating deficits in adults with autism. Biol Psychiatry 2007;61:482-6.
28. Schneider T, Przewlocki R. Behavioral alterations in rats prenatally
exposed to valproic acid. Neuropsychopharmacology 2005;30:80-9.
29. MacKay DF, Smith GCS, Dobbie R, Pell JP. Gestational age at deliv-
ery and special educational need: retrospective cohort study of 407,503
schoolchildren. PLoS Med 2010;7:e1000289.
30. Buckmayer S, Johansson S, Johansson A, Hultman CH, Sparen P,
Cnattingius S. Can association between preterm birth and autism be
explained by maternal or neonatal morbidity? Pediatrics 2009;124:
e817-25.
31. Pitzer M, Schmidt MH, Esser G, Laucht M. Child development after
maternal tocolysis with beta-sympathomimetic drugs. Child Psychiatry
Hum Dev 2001;31:165-82.
32. Bergman B, Bokstrom H, Borgas O, Enk L, Hedner T, Wangberg B.
Transfer of terbutaline across the human placenta in late pregnancy.
Obstet Gynecol Surv 1985;40:69-71.
33. Lam F, Elliott J, Jones JS, et al. Clinical issues surrounding the use of
terbutaline sulfate for preterm labor. Obstet Gynecol Surv 1998;53:
585-95.
34. Goldenberg RL. The management of preterm labor. Obstet Gynecol
2002;100:1020-37.
Editorial Commentary www.AJOG.org
94 American Journal of Obstetrics& Gynecology FEBRUARY 2011
